Abstract
Objectives- The aim of our study was to test the effect of a more viscous compound than existent hyaluronic acid formulation in helping to restore a defective glycosaminoglycan layer, and therefore in improving Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS) symptoms when administered intravesically in IC/PBS patients. Methods- A total of 23 female patients completed the study. Patients received endovesical administration of hyaluronic acid and chondroitin sulfate in normal saline, 40 ml, weekly for 12 weeks and then bi-weekly for 6 months, if there was initial response. Results- After 12 weeks treatment both Interstitial Cystitis Symptom and Problem Index (ICS1/ICPI), pelvic pain and Urgency/Frequency Symptom Scale (PUF) showed a mean significant improvement, which was maintained thereafter. The average number of voidings and mean voiding volumes revealed significant improvement after the 12 weeks' treatment period, with a significant reduction and increase, respectively. Mean voiding volume increased from 143 ml to 191, which apparently was not reflected in a corresponding reduction of number of daily voids (from 15,5 to 14). VAS values decreased from 5,4 to 3,6 (pain) and from 6,0 to 3,5 (urgency) after the treatment cycle, showing a significant improvement. Conclusions- In our preliminary experience, the administration of intravesical hyaluronic acid plus chondroitine sulphate appears to be a safe and efficacious method of treatment in IC/PBS.
| Original language | English |
|---|---|
| Pages (from-to) | 126-129 |
| Number of pages | 4 |
| Journal | Reviews on Recent Clinical Trials |
| Volume | 3 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - May 2008 |
Fingerprint
Keywords
- Chondroitine sulfate
- Hyaluronic acid
- Interstitial cystitis
- Intravesical treatment
- Painful bladder syndrome
ASJC Scopus subject areas
- Medicine(all)
- Pharmacology
Cite this
Results of endovesical hyaluronic acid/chondroitin sulfate in the treatment of interstitial cystitis/painful bladder syndrome. / Porru, Daniel; Cervigni, M.; Nasta, L.; Natale, F.; Voi, R. Lo; Tinelli, C.; Gardella, B.; Anghileri, A.; Spinillo, A.; Rovereto, B.
In: Reviews on Recent Clinical Trials, Vol. 3, No. 2, 05.2008, p. 126-129.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Results of endovesical hyaluronic acid/chondroitin sulfate in the treatment of interstitial cystitis/painful bladder syndrome
AU - Porru, Daniel
AU - Cervigni, M.
AU - Nasta, L.
AU - Natale, F.
AU - Voi, R. Lo
AU - Tinelli, C.
AU - Gardella, B.
AU - Anghileri, A.
AU - Spinillo, A.
AU - Rovereto, B.
PY - 2008/5
Y1 - 2008/5
N2 - Objectives- The aim of our study was to test the effect of a more viscous compound than existent hyaluronic acid formulation in helping to restore a defective glycosaminoglycan layer, and therefore in improving Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS) symptoms when administered intravesically in IC/PBS patients. Methods- A total of 23 female patients completed the study. Patients received endovesical administration of hyaluronic acid and chondroitin sulfate in normal saline, 40 ml, weekly for 12 weeks and then bi-weekly for 6 months, if there was initial response. Results- After 12 weeks treatment both Interstitial Cystitis Symptom and Problem Index (ICS1/ICPI), pelvic pain and Urgency/Frequency Symptom Scale (PUF) showed a mean significant improvement, which was maintained thereafter. The average number of voidings and mean voiding volumes revealed significant improvement after the 12 weeks' treatment period, with a significant reduction and increase, respectively. Mean voiding volume increased from 143 ml to 191, which apparently was not reflected in a corresponding reduction of number of daily voids (from 15,5 to 14). VAS values decreased from 5,4 to 3,6 (pain) and from 6,0 to 3,5 (urgency) after the treatment cycle, showing a significant improvement. Conclusions- In our preliminary experience, the administration of intravesical hyaluronic acid plus chondroitine sulphate appears to be a safe and efficacious method of treatment in IC/PBS.
AB - Objectives- The aim of our study was to test the effect of a more viscous compound than existent hyaluronic acid formulation in helping to restore a defective glycosaminoglycan layer, and therefore in improving Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS) symptoms when administered intravesically in IC/PBS patients. Methods- A total of 23 female patients completed the study. Patients received endovesical administration of hyaluronic acid and chondroitin sulfate in normal saline, 40 ml, weekly for 12 weeks and then bi-weekly for 6 months, if there was initial response. Results- After 12 weeks treatment both Interstitial Cystitis Symptom and Problem Index (ICS1/ICPI), pelvic pain and Urgency/Frequency Symptom Scale (PUF) showed a mean significant improvement, which was maintained thereafter. The average number of voidings and mean voiding volumes revealed significant improvement after the 12 weeks' treatment period, with a significant reduction and increase, respectively. Mean voiding volume increased from 143 ml to 191, which apparently was not reflected in a corresponding reduction of number of daily voids (from 15,5 to 14). VAS values decreased from 5,4 to 3,6 (pain) and from 6,0 to 3,5 (urgency) after the treatment cycle, showing a significant improvement. Conclusions- In our preliminary experience, the administration of intravesical hyaluronic acid plus chondroitine sulphate appears to be a safe and efficacious method of treatment in IC/PBS.
KW - Chondroitine sulfate
KW - Hyaluronic acid
KW - Interstitial cystitis
KW - Intravesical treatment
KW - Painful bladder syndrome
UR - http://www.scopus.com/inward/record.url?scp=46749158369&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=46749158369&partnerID=8YFLogxK
U2 - 10.2174/157488708784223817
DO - 10.2174/157488708784223817
M3 - Article
C2 - 18474023
AN - SCOPUS:46749158369
VL - 3
SP - 126
EP - 129
JO - Reviews on Recent Clinical Trials
JF - Reviews on Recent Clinical Trials
SN - 1574-8871
IS - 2
ER -